Want to see MANE full AI Analyst Report?
MANE Stock Chart & Stats
$76.29
--
Market closed
$76.29
--
Day’s Range― - ―
52-Week Range$32.00 - $131.24
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$5.37B
Enterprise Value$3.67B
Total Cash (Recent Filing)$390.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.71
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,778,687
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-10.94
Price to Sales (P/S)0.00
P/FCF Ratio-18.49
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-75.59
Forecast
1Y Price Target
$136.00Price Target Upside78.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Phase 2/3 Topline ResultsMeeting primary and key secondary endpoints with a favorable safety profile materially derisks VDPHL01's clinical program, strengthening the regulatory pathway. This outcome supports a potential first-in-class oral non-hormonal therapy, improving long-term commercialization and partnership prospects in a large aesthetics market.
Completed Equity Financing And Pre-funded WarrantsThe May financing meaningfully bolsters near-term liquidity and extends runway, reducing immediate financing pressure and enabling the company to advance pivotal Phase 3 studies. Durable access to capital supports execution of clinical milestones that determine long-term value creation and partner interest.
Low Debt And Higher Total AssetsA larger asset base combined with negligible debt provides balance-sheet flexibility to fund operations without heavy interest obligations. This structural liquidity buffer supports continued R&D and trial execution, helping the company sustain development momentum while minimizing leverage-related constraints.
Bears Say
Pre-revenue ProfileAbsence of commercial revenue means the business lacks internal cash generation and remains fully dependent on external funding to progress programs and scale. This structural reality increases long-term execution risk until regulatory approval, commercialization, or durable licensing/partner revenue emerges.
Accelerating Cash BurnRapidly widening operating outflows create sustained financing needs to complete pivotal trials and regulatory work. Persistent negative free cash flow increases dilution risk and constrains strategic optionality, pressuring management to secure further capital while executing on development milestones.
Sharp Deterioration In EquityA move to deeply negative equity reflects cumulative losses that weaken financial flexibility and may deter certain partners or limit funding alternatives. This structural solvency concern raises the company's dependence on capital markets and could complicate long-term strategic transactions or unfavorable financing terms.
MANE FAQ
What was Veradermics, Incorporated’s price range in the past 12 months?
Veradermics, Incorporated lowest stock price was $32.00 and its highest was $131.24 in the past 12 months.
What is Veradermics, Incorporated’s market cap?
Veradermics, Incorporated’s market cap is $5.37B.
When is Veradermics, Incorporated’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Veradermics, Incorporated’s earnings last quarter?
Currently, no data Available
Is Veradermics, Incorporated overvalued?
According to Wall Street analysts Veradermics, Incorporated’s price is currently Undervalued.
Does Veradermics, Incorporated pay dividends?
Veradermics, Incorporated does not currently pay dividends.
What is Veradermics, Incorporated’s EPS estimate?
Veradermics, Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Veradermics, Incorporated have?
Veradermics, Incorporated has 41,778,687 shares outstanding.
What happened to Veradermics, Incorporated’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Veradermics, Incorporated?
Currently, no hedge funds are holding shares in MANE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veradermics, Incorporated Stock Smart Score
Company Description
Veradermics, Incorporated
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
MANE Stock 12 Month Forecast
Average Price Target
$136.00
▲(78.27% Upside)
Vericel
―
Veracyte
―
Kiniksa Pharmaceuticals
―
Arcutis Biotherapeutics
―
Caris Life Sciences, Inc.
―
Ownership Overview
18.55% Insiders
1.03% Mutual Funds
35.56% Other Institutional Investors
39.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---